Tezspire Approved for Self-Administration in the U.S. With a New Pre-filled Pen
Now Offers Patients the Choice of Administration at Home or in a Doctor’s Office THOUSAND OAKS, Calif., Feb. 2, 2023 /PRNewswire/ — Amgen (NASDAQ:AMGN) and AstraZeneca today announced the U.S. Food and Drug Administration (FDA) has approved Tezspire® (tezepelumab-ekko) for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma.1 First approved by the […]
Continue reading »